Here, we report the first case of a SMARCB1-deficient undifferentiated carcinoma expressing high PD-L1 and responding to a PD-1 inhibitor, with low tumor mutation burden (TMB), proficient mismatch repair (MMR) and BRAF V600E mutation in the rectum. Here, SMARCB1 is linked to neoplasm.